Stefan Katharios-Lanwermeyer1, Jon-Erik Holty2, Marissa Person1, James Sejvar1, Dana Haberling1, Heather Tubbs3, Dana Meaney-Delman4, Satish K Pillai3, Nathaniel Hupert5, William A Bower1, Katherine Hendricks1. 1. Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Pulmonary, Critical Care and Sleep Medicine Section, VA Palo Alto Healthcare System Department of Medicine, Stanford University, California. 3. Division of Preparedness and Emerging Infections. 4. National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. Departments of Healthcare Policy and Research and of Medicine, Weill Medical College, Cornell University, New York Presbyterian Hospital, New York.
Abstract
BACKGROUND: Bacillus anthracis, the causative agent of anthrax, is a potential bioterrorism agent. Anthrax meningitis is a common manifestation of B. anthracis infection, has high mortality, and requires more aggressive treatment than anthrax without meningitis. Its rapid identification and treatment are essential for successful management of an anthrax mass casualty incident. METHODS: Three hundred six published reports from 1880 through 2013 met predefined inclusion criteria. We calculated descriptive statistics for abstracted cases and conducted multivariable regression on separate derivation and validation cohorts to identify clinical diagnostic and prognostic factors for anthrax meningitis. RESULTS: One hundred thirty-two of 363 (36%) cases with systemic anthrax met anthrax meningitis criteria. Severe headache, altered mental status, meningeal signs, and other neurological signs at presentation independently predicted meningitis in the derivation cohort and were tested as a 4-item assessment tool for use during anthrax mass casualty incidents. Presence of any 1 factor on admission had a sensitivity for finding anthrax meningitis of 89% (83%) in the adult (pediatric) validation cohorts. Anthrax meningitis was unlikely in the absence of any of these signs or symptoms (likelihood ratio [LR]- = 0.12 [0.19] for adult [pediatric] cohorts), while presence of 2 or more made meningitis very likely (LR+ = 26.5 [30.0]). Survival of anthrax meningitis was predicted by treatment with a bactericidal agent (P = .005) and use of multiple antimicrobials (P = .01). CONCLUSIONS: We developed an evidence-based assessment tool for screening patients for meningitis during an anthrax mass casualty incident. Its use could improve both patient outcomes and resource allocation in such an event. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Bacillus anthracis, the causative agent of anthrax, is a potential bioterrorism agent. Anthrax meningitis is a common manifestation of B. anthracisinfection, has high mortality, and requires more aggressive treatment than anthrax without meningitis. Its rapid identification and treatment are essential for successful management of an anthrax mass casualty incident. METHODS: Three hundred six published reports from 1880 through 2013 met predefined inclusion criteria. We calculated descriptive statistics for abstracted cases and conducted multivariable regression on separate derivation and validation cohorts to identify clinical diagnostic and prognostic factors for anthrax meningitis. RESULTS: One hundred thirty-two of 363 (36%) cases with systemic anthrax met anthrax meningitis criteria. Severe headache, altered mental status, meningeal signs, and other neurological signs at presentation independently predicted meningitis in the derivation cohort and were tested as a 4-item assessment tool for use during anthrax mass casualty incidents. Presence of any 1 factor on admission had a sensitivity for finding anthrax meningitis of 89% (83%) in the adult (pediatric) validation cohorts. Anthrax meningitis was unlikely in the absence of any of these signs or symptoms (likelihood ratio [LR]- = 0.12 [0.19] for adult [pediatric] cohorts), while presence of 2 or more made meningitis very likely (LR+ = 26.5 [30.0]). Survival of anthrax meningitis was predicted by treatment with a bactericidal agent (P = .005) and use of multiple antimicrobials (P = .01). CONCLUSIONS: We developed an evidence-based assessment tool for screening patients for meningitis during an anthrax mass casualty incident. Its use could improve both patient outcomes and resource allocation in such an event. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Bacillus anthracis; anthrax; mass casualty incident; meningitis; resource allocation
Authors: M Meselson; J Guillemin; M Hugh-Jones; A Langmuir; I Popova; A Shelokov; O Yampolskaya Journal: Science Date: 1994-11-18 Impact factor: 47.728
Authors: Brian Y Hwang; Geoffrey Appelboom; Amit Ayer; Christopher P Kellner; Ivan S Kotchetkov; Paul R Gigante; Raqeeb Haque; Michael Kellner; E Sander Connolly Journal: Cerebrovasc Dis Date: 2010-12-21 Impact factor: 2.762
Authors: Dena M Bravata; Ewen Wang; Jon-Erik Holty; Robyn Lewis; Paul H Wise; Smita Nayak; Hau Liu; Kathryn M McDonald; Douglas K Owens Journal: Evid Rep Technol Assess (Full Rep) Date: 2006-08
Authors: Jon-Erik C Holty; Dena M Bravata; Hau Liu; Richard A Olshen; Kathryn M McDonald; Douglas K Owens Journal: Ann Intern Med Date: 2006-02-21 Impact factor: 25.391
Authors: Joel J Gagnier; Gunver Kienle; Douglas G Altman; David Moher; Harold Sox; David Riley Journal: J Clin Epidemiol Date: 2013-09-12 Impact factor: 6.437
Authors: Mark D Sprenkle; Jayne Griffith; William Marinelli; Anne E Boyer; Conrad P Quinn; Nicki T Pesik; Alex Hoffmaster; Joseph Keenan; Billie A Juni; David D Blaney Journal: Emerg Infect Dis Date: 2014-02 Impact factor: 6.883
Authors: H S Heine; S V Shadomy; A E Boyer; L Chuvala; R Riggins; A Kesterson; J Myrick; J Craig; M G Candela; J R Barr; K Hendricks; W A Bower; H Walke; G L Drusano Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191
Authors: Christine M Szablewski; Kate Hendricks; William A Bower; Sean V Shadomy; Nathaniel Hupert Journal: Emerg Infect Dis Date: 2017-05 Impact factor: 6.883
Authors: Maurizio Guastalegname; Valeria Rondinone; Giuseppe Lucifora; Alfredo Vallone; Laura D'Argenio; Giovanni Petracca; Antonia Giordano; Luigina Serrecchia; Viviana Manzulli; Lorenzo Pace; Antonio Fasanella; Domenico Simone; Dora Cipolletta; Domenico Galante Journal: Life (Basel) Date: 2022-06-17